ClinicalTrials.govpublic full text
Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
carcinoma, hepatocellular, hepatocellular carcinoma, mitogen-activated extracellular-signal-regulated kinase (mek) inhibitor, objective tumor response rate (orr), modified recist criteria, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 883544
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.